UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):July 7, 2014
MMRGLOBAL, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE | | 000-51134 | | 33-0892797 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| | | | |
4401 WILSHIRE BLVD., SUITE 200
LOS ANGELES, CA 90010 |
(Address of Principal Executive Offices)
(Zip Code) |
(310) 476-7002
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement
On July 7, 2014, MMRGlobal, Inc., a Delaware corporation (the "Company"), announced that it entered into a Non-Exclusive License Agreement (the "Agreement") with Claydata Pty Ltd. ("Claydata") effective June 30, 2014.
Pursuant to the terms of the Agreement, Claydata received a Non-Exclusive License to the Company's family of patents, and the right to resell the Company's MyMedicalRecords Personal Health Record (the "MMR-PHR") or utilize selected features in the MMR-PHR in Australia, New Zealand and the US.
In addition to the above terms, the Agreement contains customary provisions, including the term of the Agreement, representations, warranties, indemnities and confidentiality by each of the Company and Claydata.
The above summary does not purport to be a complete description of the terms of the Agreement and is qualified in its entirety by reference to the Agreement, which the Company will file as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. Portions of the Agreement may be omitted in accordance with a request for confidential treatment that the Company expects to submit to the U.S. Securities and Exchange Commission.
In addition, a copy of the press release announcing on July 7, 2014 the Agreement is attached hereto as Exhibit 99.1 and is hereby incorporated by this reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description |
99.1 | Press Release dated July 7, 2014. |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | MMRGLOBAL, INC.
|
July 11, 2014 | | By: /s/ Robert H. Lorsch
Robert H. Lorsch
Chief Executive Officer |
EXHIBIT INDEX
